Open Access

PROSER2 is a poor prognostic biomarker for patients with osteosarcoma and promotes proliferation, migration and invasion of osteosarcoma cells

  • Authors:
    • Zhengjiang Li
    • Yan Zhang
    • Yongkui Li
    • Shuxing Xing
    • Shunqiang Li
    • Jing Lyu
    • Zhaonan Ban
  • View Affiliations

  • Published online on: November 8, 2022     https://doi.org/10.3892/etm.2022.11686
  • Article Number: 750
  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Proline‑ and serine‑rich 2 (PROSER2) is encoded by the 47th open reading frame on human chromosome 10. Bioinformatic analysis has shown PROSER2 was significantly correlated with prognostic outcome of osteosarcoma patients. Its role in the progression and metastasis of human osteosarcoma has not been elucidated until now. Bioinformatics analysis was performed on 101 patients with osteosarcoma from The Cancer Genome Atlas database. High levels of PROSER2 were associated with a poor prognosis in patients with osteosarcoma. PROSER2 expression was significantly upregulated in clinical specimens from patients with osteosarcoma and osteosarcoma cell lines. MTT assay was performed to test the cell viability and Transwell assay was used to test the migration and invasion of MG63 cells. PROSER2 knockdown inhibited the viability, migration and invasion of MG63 cells. Gene Set Enrichment Analysis and Gene Ontology/Kyoto Encyclopedia of Genes and Genomes analysis showed that the differentially expressed genes were primarily involved in ‘calcium signaling pathway’ and ‘Wnt signaling’ in patients with osteosarcoma and high PROSER2 expression. Western blotting analysis revealed that PROSER2 regulated migration and invasion of osteosarcoma via the Wnt/nuclear factor of activated T‑cells (NFAT)c1 signaling pathway. In conclusion, PROSER2 promoted the proliferation, migration and invasion of osteosarcoma cells via the Wnt/Ca2+/NFATc1 signaling pathway by increasing nuclear localization of NFATc1.

Related Articles

Journal Cover

December-2022
Volume 24 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Li Z, Zhang Y, Li Y, Xing S, Li S, Lyu J and Ban Z: PROSER2 is a poor prognostic biomarker for patients with osteosarcoma and promotes proliferation, migration and invasion of osteosarcoma cells. Exp Ther Med 24: 750, 2022
APA
Li, Z., Zhang, Y., Li, Y., Xing, S., Li, S., Lyu, J., & Ban, Z. (2022). PROSER2 is a poor prognostic biomarker for patients with osteosarcoma and promotes proliferation, migration and invasion of osteosarcoma cells. Experimental and Therapeutic Medicine, 24, 750. https://doi.org/10.3892/etm.2022.11686
MLA
Li, Z., Zhang, Y., Li, Y., Xing, S., Li, S., Lyu, J., Ban, Z."PROSER2 is a poor prognostic biomarker for patients with osteosarcoma and promotes proliferation, migration and invasion of osteosarcoma cells". Experimental and Therapeutic Medicine 24.6 (2022): 750.
Chicago
Li, Z., Zhang, Y., Li, Y., Xing, S., Li, S., Lyu, J., Ban, Z."PROSER2 is a poor prognostic biomarker for patients with osteosarcoma and promotes proliferation, migration and invasion of osteosarcoma cells". Experimental and Therapeutic Medicine 24, no. 6 (2022): 750. https://doi.org/10.3892/etm.2022.11686